Why this broker sees little upside to the Polynovo (ASX:PNV) share price right now

Bell Potter has cut its Polynovo Ltd (ASX: PNV) share price target after the company missed its growth forecasts. Here's the rundown.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

The Polynovo Ltd (ASX: PNV) share price was one of the best performing ASX 200 healthcare shares in 2020, running from $1.97 to $3.88.

But when the company's share price started to turn in the wrong direction, it fell and it fell fast. 

It wasn't just the trading update

Polynovo released a trading update on 12 January 2021 which saw its shares crash 13% on the day.

But it wasn't just the trading update to point the finger at for Polynovo's significant share price decline. Its shares had already slumped from $3.88 to $3.39 or 12% before the announcement, almost a tell tale of the bad news brewing. 

Furthermore, the S&P/ASX 200 Health Care (ASX: XHJ) has also fallen 4.3% in the new year. Adding further insult to injury for the healthcare sector.  

Bell Potter disappointed with first half FY21 trading update 

Bell Potter reports: "Polynovo announced a relatively disappointing trading update, with 1H FY21 sales growth of 31% vs the pcp well below our forecasts, consensus and management expectations".

In the company's November 2020 annual general meeting, Polynovo's NovoSorb BTM product experienced very strong growth from $9.3 million in FY19 to $19.06 million in FY20.

Polynovo managing director Paul Brennan said at the time the company would "continue to harness this momentum to double our revenues again in FY21".

Bell Potter's report notes that "expectations were broadly that sales would double in FY21 vs FY20".

It noted that management also "tempered expectations around growth for the second half given the uncertainty in patient volumes". 

The broker did highlight some small positives including management's strong update on new accounts, with successful customers additions and ongoing efforts to drive growth with integrated distribution networks. Those new customers may start to become more active users of Novosorb BTM in the coming months, especially if patient volumes recover well in a post-vaccine environment. 

Overall, Bell Potter reduced its Polynovo share price target from $3.20 to $2.90 with a hold rating. The Polynovo share price is trading up 4.48% at $2.80 at the time of writing. 

Lina Lim has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of POLYNOVO FPO. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Man in business suit carries box of personal effects
Healthcare Shares

Monash IVF shares jump 9% as CEO quits after second embryo incident

Two incidents at its clinics have cost this CEO his job.

Read more »

Woman with an amazed expression has her hands and arms out with a laptop in front of her.
Share Gainers

Guess which ASX 200 stock turned $5,000 into $34,264 in just three years!

Investors have been piling into this ASX 200 stock for years, sending the share price soaring.

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Healthcare Shares

Cochlear shares sink 9% on guidance downgrade

Investors haven't responded positively to this update. Let's dig deeper into it.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Telix shares push higher on investor day update

This radiopharmaceuticals company has grand plans for the future.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

3 leading ASX healthcare shares with global reach

These 3 healthcare companies are having an outsized impact far beyond local markets.

Read more »

Man looks shocked as he works on laptop on top a skyscraper with stockmarket figures in graphic behind him.
Healthcare Shares

Macquarie tips more than 100% upside for this ASX All Ords healthcare stock

This company could be set to soar.

Read more »

A little boy, soon to be a brother, kisses and holds his mum's pregnant tummy.
Healthcare Shares

Monash IVF shares fall 25% following second embryo incident

Its been a forgettable start to 2025 for Monash IVF shareholders.

Read more »

Shot of two young scientists using a laptop in a laboratory.
Healthcare Shares

Buying CSL shares? Meet your new board director

CSL’s new board director has spent the last 11 years in an executive role at Australia’s $240 billion Future Fund.

Read more »